secwatch.observer — SEC 8-K summary
======================================

Issuer:     Emmaus Life Sciences, Inc. (EMMA)
CIK:        0000822370
Form:       8-K
Filed at:   2026-03-31T23:59:59+00:00
Accession:  0001213900-26-036886
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Emmaus 2025 net revenue $12.5M (-25% YoY); net loss widens to $7.2M
-------------------------------------------------------------------

- Net revenue $12.5M vs $16.7M in 2024; net loss $7.2M ($0.11/sh) vs $6.5M ($0.10/sh).
- Income from operations $0.2M, improved from operating loss of $1.9M; operating expenses fell 34% to $11.4M.
- Cash and equivalents $2.1M at Dec 31, 2025, up from $1.4M at Dec 31, 2024.
- Entered license/distribution deal with NeoImmuneTech for U.S. operations, expected Q2 2026.
- Revenue drop driven by generic L-Glutamine competition in U.S., partially offset by MENA growth.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/822370/000121390026036886/0001213900-26-036886-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/822370/000121390026036886/ea0283899-8k_emmaus.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-036886

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer